10.6084/m9.figshare.5701258.v1 Zuhua Chen Zuhua Chen Zhentao Liu Zhentao Liu Wenwen Huang Wenwen Huang Zhongwu Li Zhongwu Li Jianling Zou Jianling Zou Jingyuan Wang Jingyuan Wang Xiaoting Lin Xiaoting Lin Beifang Li Beifang Li Dongshao Chen Dongshao Chen Yanting Hu Yanting Hu Jiafu Ji Jiafu Ji Jing Gao Jing Gao Lin Shen Lin Shen MOESM3 of Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways Springer Nature 2017 Gimatecan Patient-derived xenografts Gastric cancer MAPK pathway 2017-12-13 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_Gimatecan_exerts_potent_antitumor_activity_against_gastric_cancer_in_vitro_and_in_vivo_via_AKT_and_MAPK_signaling_pathways/5701258 Additional file 3: Figure S3. Gimatecan exerts antitumor activity via AKT and MAPK signaling pathways in HGC27 cells. (A) Gimatecan significantly inhibited the expression of TopI, pAKT, pMEK, and pERK, and activated the expression of p-p38 MAPK and pJUNK2 in HGC27 cells. Cells were starved in serum-free medium overnight, exposed to gimatecan or irinotecan for 48 h and harvested at 70–80% confluence. Total protein of HGC27 was extracted and the expression of TopI, pAKT, pMEK, pERK, p-p38 MAPK and pJNK2 were assessed by western-blotting followed by quantification and normalization by ImageJ. All data are means ± SD of three independent experiments. Compared with controls, *, p < 0.05.